Virtual Library
Start Your Search
M. Anraku
Author of
-
+
MINI 32 - Topics in Localized Lung Cancer (ID 166)
- Event: WCLC 2015
- Type: Mini Oral
- Track: Treatment of Localized Disease - NSCLC
- Presentations: 1
- Moderators:D. Boffa, T. D'Amico
- Coordinates: 9/09/2015, 18:30 - 20:00, 201+203
-
+
MINI32.06 - Clinical Impacts of Tumor Hypoxia Imaging with FAZA and ATSM PET in NSCLC (ID 182)
18:30 - 20:00 | Author(s): M. Anraku
- Abstract
- Presentation
Background:
The noninvasive dynamic characterization of hypoxia using molecular imaging approaches is supportive for evaluation of malignant tumor. In this study, we evaluated the clinicopathological impact of newly developed tumor hypoxia PET tests for localized non-small cell lung cancer (NSCLC).
Methods:
Forty-nine patients with localized NSCLC were enrolled[F1] [木下智成2] . They underwent chest hypoxia PET tests, namely [18]F-fluoroazomycin arabinoside (FAZA) and/or [62]Cu-diacetyl-bis (N4)-methylsemithiocarbazone (ATSM) PET in addition to routine whole-body [18]F-fluorodeoxyglucose (FDG) PET before treatment. Uptake of hypoxic tracers was quantified by calculating maximum standard uptake values (SUVmax) and tumor muscle ratios (TMR).
Results:
The uptake of [18]F-FAZA were in positive proportion to that of [62]Cu-ATSM (P < 0.05). Neutrophil lymphocyte ratio and tumor size were significantly correlated with uptake both in [18]F-FAZA (P < 0.01) and [62]Cu-ATSM (P < 0.05 in [18]F-FAZA and [62]Cu-ATSM). Pathologically, the case with vascular or pleural invasion, which indicate tumor malignancy, had higher uptake of [18]F-FAZA (P < 0.05). Those accumulations increased according to advanced TNM staging (P < 0.05). The patient with higher uptake of these tracers significantly had a poorer overall survival (P < 0.01 in [18]F-FAZA and P < 0.05 in [62]Cu-ATSM), and progression-free survival (P < 0.01 in [18]F-FAZA and P < 0.05 in [62]Cu-ATSM).
Conclusion:
[18]F-FAZA and [62]Cu-ATSM can provide useful information on tumor malignancy and prognosis, and might contribute toward guiding individualization of treatment of localized NSCLC. Figure 1Figure 2
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
P2.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 210)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Localized Disease - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.02-002 - Impact of Multiple Cancer Treatment History on Outcome in Patients with Surgically Resected Non-Small Cell Lung Cancer (ID 841)
09:30 - 17:00 | Author(s): M. Anraku
- Abstract
Background:
It has been common that patients with previous cancer treatment history undergo curative resection of non-small cell lung cancer (NSCLC); however, the impact of multiple cancer history on outcome after surgery remains unclear.
Methods:
We conducted a retrospective study by using data from patients who underwent curative surgical resection for NSCLC between 1998 and 2011 at our institution. Data recorded for analyses were: age, gender, clinical and pathological stages of NSCLC, mode of surgical resection, comorbidities, pre-treatment serum CEA level, smoking history, and previous cancer history (organ, histologic type, number of cancer treated). The chi-square test and Wilcoxon test were used to analyze the factors between groups (ie, cases with previous cancer history versus those without cancer history). The Kaplan-Meier method was used to estimate survival rates. The log-rank test was applied to compare the survival rates between the groups. A p value less than 0.05 was considered as statistically significant.
Results:
In the study, 229 out of 923 cases (24.8%) had previous cancer treatment history. In the 229 cases, 194 had single cancer treatment history, 30 had double cancer treatment history, and 5 had triple cancer treatment history. Types of cancer treated were: colorectal cancer (n=51), lung cancer (n=30), hepatocellular carcinoma (n=25), breast cancer (n=16), esophageal cancer (n=15), renal cell cancer (n=12), cancers of head and neck (n=11), and others (n=56). There were significantly increased rate of having cancer treatment history in the later study period (2005-2011) compared to a rate in the earlier study period (1998-2004)(30% versus 15%, p<0.01). When comparing to patients without previous cancer history, those with previous cancer history were significantly older (69.1 versus 66.4 years, p<0.01), and had higher smoking history rate (75.1% versus 64.7%, p<0.01). On the other hand, the proportion of stage I NSCLC was significantly higher in cases with previous cancer history than those without previous cancer history (95.2% versus 74.4%, p<0.01). All cases with triple cancer treatment history had clinical and pathological stage I NSCLCs. The survival outcome after surgical resection was significantly better in cases without previous cancer treatment history than those with cancer treatment history (5-year survival rates; 79% versus 75%). In those with cancer treatment history, cases with 2 or more cancers treated had worse outcome than those with only one cancer treated before lung cancer resection (5-year survival rates; 69% versus 76%).
Conclusion:
Although the previous cancer treatment history and the number of cancers treated affected the outcome of patients who underwent curative lung cancer resection, the 5-year survival rate of 75% was achieved in the population. In those with previous cancer history, lung cancer tends to be found in early stage because of the periodical check-up for previous cancers. Therefore, surgical resection of newly detected NSCLC can be a viable option, if the previously treated cancer(s) are well controlled and the new lung cancer is deemed resectable.
